Form PTO-1449 U.S. I partment of Commerce (REV. 8-83) Patent and Trademark Office			Atty. Doct 2001796-0008	In re Application No. 10/087,667		
INFORMATION DISCHOSURE STATEMENT (Use several sheets if necessary)		Applicant: A.John Bra	Applicant: A.John Bramley			
		Filing Date:	Group:			
		February 28, 2002	1632			
U.S. PATENT	DOCUMENTS	-			-	
Examiner's	U.S. Patent No.	Applicant	Issue Date	Class	Subclass	
Initials						
OU	*4,931,390	Recsei	June 5, 1990	435	183	
1	*5,011,772	Recsei	April 30, 1991	435	69.1	
	*5,124,145	Sordillo et al.	June 23, 1992	424	85.5	
	*5,189,015	Höök et al.	February 23, 1993	514	2	
	*5,234,684	Sordillo et al.	August 10, 1993	424	85.5	
	*5,342,612	Daley et al.	August 30, 1994	424	85.1	
	*5,607,919	Bojsen et al.	March 4, 1997	514	12	
	*6,028,051	Climo et al.	February 22, 2000	514	2	
U.S. PATENT	APPLICATIONS	-	<u> </u>			
Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:	
		\$ 15 day				
	FENT DOCUMENTS	Î.				
Examiner's Initials	Document No.	Country	Date	Translati		
	+WYO 07/0 C0 C4			Yes	No	
	*WO 87/06264	International	22 October 1987			
. <u></u>	*WO 96/35793	International	14 November 1996			
	*WO 99/05289	International	4 February 1999			
	*EP 0 359 873	Europe	19 September 1988			
	*EP_0-759 473	Europe	23 August 1995		1.	
OTHER DOCU	JMENTS			,	··	
Examiner's Initials	Citation (Including Auth	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)				
VED 2002	*Archer, et al., "Human Transfer of the hGH Ge Retrovirus Vectors", Pro 91:6840-44, July 1994.	*Archer, et al., "Human Growth Hormone (hGH) Secretion in Milk of Goats After Direct Transfer of the hGH Gene into the Mammary Gland by Using Replication-Defective Retrovirus Vectors", <i>Proc. Natl.Acad. Sci.</i> 91:6840-44, July 1994.				
<u> </u>		*Auldist, et al., "Changes in the Composition of Milk from Healthy and Mastitic Dairy Cows During the Lactation Cycle", Aust. J. Exp. Agricul. 35: 427-36, 1995.				
	*Auldist, et al., "Effect of Somatic Cell Count and Stage of Lactation on the Quality and Storage Life of Ultra High Temperature Milk", J. Dairy Res. 63: 377-386, 1996.					
	= Stotage title of Offiavill	gir remperature win	K, J. Dairy Res. 03. 311	300, 1370.		

Ju Would 2/3/04

	Z 01P			
Form PTO-1449 (REV. 8-83)	X.S. Description of Commerce	Atty. Dock	In re Application No.	
	M or g and Trademark Office	2001796-0008	10/087,667	
INFORMATION DISCLOSURE STATEMENT (Use several sheers if necessary)		Applicant: A.John Bram		
		Filing Date: February 28, 2002	Group:	
	Dairy Sci. 74: 369-88, 1991.	1 - 501.002		
	*Bramley, et al., "Effects of Lysostaphin on Mammary Gland", Research in Veterinary So	Staphylococcus Aureus Inficience,49: 120-21; 1990.	fections of the Mouse	
	*Bramley, et al., "Reviews of the Progress of Dairy Science: Mastitic Control - Progress and Prospects" Journal of Dairy Research, 51, 481-512, 1984.			
	*Chandler, R.L., "Experimental Bacterial Mastitis in the Mouse", J. Med. Microbiol. 3: 273-82, 1970.			
·	*Chomczynski, et al., "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction", Anal. Biochem. 162: 156-59, 1987.			
	*Craven, et al., "Phagocytosis of Staphylococcus Aureus by Bovine Mammary Gland Macrophages and Intracellular Protection from Antibiotic Action in Vitor and In Vivo", J. Dairy Res. 51: 513-23, 1984.			
<u></u> -	*Craven, et al., "Antibiotic Activity Against Intraleukocytic Staphylococcus Aureus in Vitro and In Experimental Mastitis in Mice", Am. J. Vet. Res, 44:(4), 709-12, 1983.			
	*Daley, et al., "Lysostaphin: Immunogenicity of Locally Administered Recombinant Protein Used in Mastitis Therapy", Veterinary Immunology and Immunopathology, 31: 301-12, 1992.			
	*Derbyshire, et al., "Immunization Against Experimental Staphylococcal Mastitis in the Goat by the Intramammary Infusion of Cell-Toxojd Vaccine" Res. Vet. Sci., 10:559-64, 1969.			
	*Ebert, et al., "Transgenic Production of a Val Activator in Goat Milk: Generation of Transge Bio/Technology, 9: 835-38, 1991.	riant of Human Tissue-Typenic Goats and Analysis of	e Plasminogen Expression",	
	*Gordon, et al., "Production of Human Tissue Milk", Bio/Technology, 5: 1183-87, 1987.			
	*Harmon, et al., "Concentration of Lactoferring Changes Occurring during Mastins" Am. J. Ve	in Milk of Normal Lactat t. Res.36: 1001-1007, 197	ing Cows and	
	*Heinrich, et al., "The Molecular Organization Repeated in Tandem", Mol. Gen Genet, 209:50	of the Lysostaphin Gene 63-69, 1987.	and its Sequences	
^ 8	*Jacob, et al., "Potential Therapeutic Application Agents of Animal Origin", Ciba. Found. Symp	. 186 : 197-216, discussion	n, 216-23, 1994.	
2002 2002 1600/290	*Kagan, et al., "Defensins: A Family of Antim 87: 131-49, 1994.	icrobial and Cytotoxic Per	otides", Toxicology,	
三 1. 7 1. 7 1. 7 1. 7	*Kerr, et al., "Expression of Jet-Injected Plasm Lymph Nodes Draining the Injection Site", NO	OT MUCH HERE.	11	
JEC JUL SH GEN	*Klei, et al., "Effects of Milk Somatic Cell Col Dairy Sci. 81:1205-13, 1998.			
T D	*Kossaibati, et al., "Incidence of Clinical Mast 143:649-53, 1998.		į.	
	*Krimpenford, et a., "Generation of Transgenic Production," Bio/Technology, 9: 844-47, 1991.		j	
	*Liang, et al., "Molecular Cloning and Nucleot	ide Sequence of the B-Lyti	c Protease Gene	

ytic Protease Gene

Tor World 2/3/04

Form PTO/1449	·U.S. Deartment of Commerce	Atty. Dock	In re Application No.	
(REV. 8-83) JUL (Patent and Trademark Office	2001796-0008	10/087,667	
		Applicant: A.John Bramley		
	DISCOSURE STATEMENT	Filing Date:	Group:	
(Use severa	sneets if necessary)	February 28, 2002		
_	from Achromobacter Lyticus" Journal of Bac	cteriology, 172(11): 6506-	1; 1990.	
	*Maga, et al., "Antimicrobial Properties of H Food Prot. 61: 52-56, 1998.	uman Lysozyme Transgen	ic Mouse Milk", J.	
90	*Maga, et al., "The Effect of Mammary Gland Expression of Human Lysozyme on the Properties of Milk From Transgenic Mice", J. Dairy Sci. 78: 2645-52, 1995.			
t	*Myllys, et al., "Bovine Mastitis in Finland in 1988 and 1995Changes in Prevalence and Antimicrobial Resistance", Acta Vet. Scand. 39: 119-126, 1998.			
	*Nickerson, et al., "Symposium: Mastitis in Dairy Heifers, Mastitis in Dairy Heifers: Initial Studies on Prevalence and Control", <i>J Dairy Sci</i> , 78: 1607-18, 1995.			
	*Nuijens, et al., "Characterization of Recombinant Human Lactoferrin Secreted in Milk of Transgenic Mice-" The Journal of Biological Chemistry, 272 (13): 8802-07, 1997.			
•	*Oldham, et al., "Lysostaphin: Use of a Recombinant Bactericidal Enzyme as a Mastitis Therapeutic", J. Dairy Sci., 74: 41/75-82, 1991.			
: AW	*Platenburg, et al., "Expression of Human Lactoferrin Milk of Transgenic Mice", Transgenic Res. 3: 99-108, 1994.			
- QW	*Plaut, et al., "Integration of the lacZ Gene into the Mammary Gland Using an Adenovirus Vector", Journal of Dairy Science, 80:1, 1997.			
(*Recsei, et al., "Cloning, Sequence, and Expression of the Lysostaphin Gene From Staphylococcus Simulans", <i>Proc. Natl. Acad. Sci., USA</i> , 84: 1127-31, 1987.			
	*Reiter, B., "Review of the Progress of Dairy Science: Antimicrobial Systems in Milk", J. Dairy Res. 45: 131-47, 1978.			
	*Sambrook, et al., Molecular Cloning: A Lab	ooratøry Manual, 2 nd Ed., 1	989.	
	*Schindler, et al., "Lysostaphin: A New Bateriolytic Agent For the Staphylococcus. Proc. Natl. Acad. Sci. U.S.A. 51: 414-421, 1964.			
	*Schnieke, et al., "Human Factor IX Transgenic Sheep Produced by Transfer of Nuclei From Transfected Fetal Fibroblasts", Science, 2/18: 2130-33, 1997.			
	*Shockman, et al., "Stucture, Function, and A Bacteria", Annu. Rev. Microbiol. 37: 501-27,		Gram-Positive	
VED 2002 1600/290	*Sutra, et al., "Virulence Factors Involved in Infections Due to Staphylococcus Aureaus",			
	*Takahashi, et al., "Nonspecific Antibacterial Human Oral Bacterial Pathogens", J. Dairy S		vs Immunized with	
Ö.	*Thumm, et al., "Studies on Prolysostaphin Processing and Characterization of the Lysostaphin Immunity Factor (Lif) of Staphylococcus Simulans Biovar Staphylolyticus" 5Molecular Microbiology, 23(6), 1251-65, 1997.			
۲	*Verdi, et al., "Variability in True Protein, Ca High and Low Somatic Cell Milks", J. Dairy		, and Proteolysis in	
	*Wall, et al., "High-Level Synthesis of a Hete of Transgenic Swipe" Proc. Natl. Acad Sci. L.	•	he Mammary Glands	

Joe Worland





JUL 1 7 2002 TECH CENTER 1600/2900

Form PTO-1449	U.S. Department of Commerce	Atty. Docket:	In re Application No.	
(REV. 8-83)	Patent and Trademark Office	2001796-0008	10/087,667	
		Applicant: A.John Bramley		
INFORMATION DISCLOSURE STATEMENT		Filing Date:	Group:	
(Use several sheets if necessary)		February 28, 2002		
	*Watson, et al., "A Field Trial to Test the Efficacy of a Staphylococcal Mastitis Vaccine in Commercial Dairies in Australia",			
	*Williamson, et al., "Expression of Lysostaphin in the Milk of Transgenic Animals to Combat Staphylococcal Mastistis", J. Appl Bacterial. 67:6, xxi, 1986.			
· QW	*Williamson, et al., "Expression of the Lysostaphin Gene of Staphylococcus Simulans in a Eukaryotic System", Applied and Environment Microbiology, 60:3, 771-76, March, 1994.			
•	*Wilson, et al., "Bovine Mastitis Pathogens in New York an Pennsylvania: Prevalence and Effects on Somatic Cell Count and Milk Production", J. Dairy Sci. 80: 2592-98, 1997.			
•	*Wright, et al., "High Level Expression of Active Human Alpha-1-Antitrypsin in the Milk of Transgenic Sheep", Bio/Technology, 9:830-34, 1991.			
	*Yamada, et al., "An Autolysin Ring Associated with Cell Separation of Staphylococcus Aureus", J. Bacterial. 178: 1565-71, 1996.			
	*Yancey, et al., "Activity of Antibiodics Against Staphylococcus Aureus Within Polymorphonuclear Neutrophils", Eur. J. Clin. Microbiol. Infect. Dis. 10:107-113, 1991.			
	*Yarus, et al., "Production of Active Bovine Trachael Antimicrobial Peptide in Milk of Transgenic Mice", Proc. Natl. Acad. Sci. USA, 93, 14118-21, November, 1996.			
	*Zavizion, et al., "Effects of Staphylococcus Aureus Toxins on the Growth of Bovine Maramary Epithelial Cells (MAC-T) in Culture", J. Dairy Sci., 78, 277-84, 1995.			
EXAMINER	Joe Worler 1	ATE CONSIDERED	213/04	
	l.			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

3411860